Provided by Tiger Trade Technology Pte. Ltd.

KraneShares MSCI All China Health Care Index ETF

17.74
-0.0600-0.34%
Post-market: 17.800.0600+0.34%19:30 EDT
Volume:28.78K
Turnover:509.79K
Market Cap:104.67M
PE:- -
High:17.93
Open:17.89
Low:17.60
Close:17.80
52wk High:21.50
52wk Low:14.38
Shares:5.90M
Float Shares:5.90M
Volume Ratio:0.55
T/O Rate:0.49%
Dividend:0.71
Dividend Rate:4.03%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

WuXi XDC Grants 342,300 Restricted Shares to Employees Under 2024 Share Scheme

Reuters
·
Aug 25

China's Innovent Biologics H1 Revenue, Profit Rise on Strong Product Sales

Reuters
·
Aug 25

WuXi Biologics Reports Strong Profitable Growth in H1 2026

THOMSON REUTERS
·
Aug 25

WuXi Biologics H1 Net Profit up on Margin Expansion

Reuters
·
Aug 25

Wuxi Bio's Interim Results Exceed Expectations and Break Broker Targets, with Accelerated Manufacturing Growth Reinforcing Long-Term Investment Thesis

Stock News
·
Aug 25

Market Sentiment Stabilizes as Sanctions Prove Largely Symbolic; Tech Benchmarks Surge on Potential Dovish Fed Signals

Stock News
·
Aug 25

CSPC Pharma's Recombinant RSV Vaccine Wins US Clinical Trial Clearance

Stock News
·
Aug 25

CSPC Says FDA Clears RSV Vaccine Candidate SYS 6057 for US Clinical Trial

Reuters
·
Aug 25

CSPC Pharmaceutical - Recombinant Respiratory Syncytial Virus Vaccine (Sys6057) Obtains Clinical Trial Approval in U.S.

THOMSON REUTERS
·
Aug 25

CSPC Pharmaceutical - Sys6057 Receives Nmpa Approval on July 30, 2026 to Conduct Clinical Trials in China

THOMSON REUTERS
·
Aug 25

Innovent Biologics' H1 Profit Jumps 50%

MT Newswires Live
·
Aug 25

Innovent Biologics - Re-Designates Ronald Hao Xi Ede as Non-Executive Director Effective September 1, 2026

THOMSON REUTERS
·
Aug 25

WuXi Biologics Posts Higher Adjusted Attributable Profit in H1

MT Newswires Live
·
Aug 25

Innovent Announces 2026 Interim Results and Business Updates

THOMSON REUTERS
·
Aug 25

INNOVENT BIO Reports First-Half Profit of RMB 1.253 Billion, Up 50.2% Year-on-Year

Stock News
·
Aug 25

Innovent Biologics - Potential to Maintain Rapid Revenue Growth to RMB35 Bln to RMB40 Bln Total Revenue by 2030

THOMSON REUTERS
·
Aug 25

WuXi Biologics Logs HY Net Profit Attributable RMB 2,439.8 Mln

Reuters
·
Aug 25

Innovent Biologics H1 FY26 IFRS Profit Climbs 50.2% to RMB 1.25 Billion; Revenue Rises 44.8% to RMB 8.62 Billion

Reuters
·
Aug 25

WUXI BIO reports 4.3% rise in interim net profit to RMB 2.44 billion

Stock News
·
Aug 25

Innovent Biologics H1 Revenue RMB 8,617.8 Million

THOMSON REUTERS
·
Aug 25